Pain, sleep and anxiety rarely arrive one at a time, and cannabis and CBD products are marketed heavily at all three. No cannabis-based product carries FDA approval for any of them, while several non-cannabis approaches carry a first-line or moderate-evidence recommendation from major guideline bodies. This guide lays out what the condition-specific alternatives actually are, how to weigh the evidence against what you can realistically access, and a worksheet for sizing up any option — cannabis or otherwise — before you spend money on it.
What condition-specific alternatives deserve a closer look
The three complaints respond to different evidence bases, so it helps to separate them rather than treat “pain, sleep and anxiety” as one bucket.
For chronic pain
- The American College of Physicians’ chronic low-back pain guideline recommends non-drug approaches as the first step, including exercise, cognitive behavioral therapy (CBT) and mindfulness-based stress reduction (MBSR), the latter based on moderate-quality evidence.
- NIH’s National Center for Complementary and Integrative Health (NCCIH) rates acupuncture, tai chi, yoga, progressive muscle relaxation and spinal manipulation as having low- to moderate-quality evidence for chronic low-back pain, with acupuncture additionally supported for neck pain.
- In an NIH/NCCIH-funded trial comparing CBT, MBSR and usual care for chronic low-back pain, 45% of the CBT group and 44% of the MBSR group reported meaningful improvement in back pain, compared with 27% in the usual-care group.
For sleep
- Cognitive behavioral therapy for insomnia (CBT-I) is recommended by the American College of Physicians as the first-line treatment for chronic insomnia in all adult patients — ahead of medication.
- A 2015 systematic review and meta-analysis in the Annals of Internal Medicine found CBT-I produces clinically meaningful improvements in sleep-onset latency, time awake after sleep onset, and sleep efficiency in adults with chronic insomnia.
- Those improvements in sleep-onset latency and time awake after sleep onset have held up in long-term randomized trials followed for up to 24 months.
For anxiety
- NCCIH’s evidence summary on anxiety describes mindfulness meditation as having small-to-modest benefit for anxiety-related symptoms, citing a 2014 systematic review and meta-analysis of 47 trials (3,515 participants) that found moderate evidence of improved anxiety from mindfulness meditation programs.
- A published review of mind-body interventions for anxiety disorders found the highest-quality evidence among such approaches belongs to yoga, mindfulness-based interventions, and applied relaxation — and found mindfulness-based approaches performed comparably to, not better or worse than, standard CBT, behavioral therapy or medication in several of the studies reviewed.
None of this is a ranking of “best” options — it’s a map of where the evidence is strongest, so a reader can bring an informed starting point to a conversation with a clinician.
Weighing evidence strength against what you can actually access
Evidence grade is only half the decision. NCCIH is explicit that the amount and quality of evidence varies by approach and by condition, and that these are generally modest-effect options, not cures — so the practical question is whether a given approach is something you can get to and actually stick with. (If you want to see how we weigh evidence grades like these before writing about them, our review process walks through it.)
Three things tend to decide that in practice:
- Access. CBT and CBT-I require a trained provider; not every area has one, and not every plan covers it. Exercise, sleep-hygiene changes and relaxation-based approaches require no provider at all, which is part of why they appear in nearly every guideline as a reasonable starting point.
- Time commitment. CBT-I protocols typically run several structured weeks; a faster-acting option trades a shorter evidence trail for a quicker initial result.
- Personal preference and prior experience. A reader who has already tried and abandoned CBT for a different reason isn’t well served by a guide that only points back to CBT. Multiple approaches above carry supporting evidence; the right one is the one a person will actually follow through on.
Where a condition involves other diagnoses — cardiovascular disease, liver disease, pregnancy, or concurrent prescription medication — evidence quality for any self-directed approach matters less than getting a clinician’s input first, since several of these interventions, including exercise programs, carry their own contraindications.
A worksheet for comparing any option before you commit
Before trying a new approach — cannabis-based or not — it helps to write down the same five things every time, so comparisons are apples to apples instead of ad to ad:
- What it is and how it’s delivered. A structured therapy program, a device, a supplement, an exercise regimen — name the actual modality, not the marketing category.
- Evidence grade for your specific complaint. Is this first-line (like CBT-I for insomnia), moderate-quality (like MBSR for low-back pain), or preliminary — and for which condition specifically, since an approach can be well-supported for one complaint and barely studied for another.
- Access barrier. Provider required or not, cost, insurance coverage, wait time, and whether it’s realistic for your location and schedule.
- Who stands behind it. A licensed clinician, a certified program, or a product with no named credentialing body — this is where unproven commercial claims usually surface.
- The open question to bring to a clinician. Every approach has one honest unresolved point — a drug interaction, a contraindication, or simply “will this work for my diagnosis.” Write it down before you ask, not after.
Filling this out for two or three options side by side usually makes the decision easier than reading another article.
Where cannabis actually fits
The FDA has not approved any product containing whole cannabis plant material for any purpose. The agency has approved synthetic THC-based medications — dronabinol and nabilone — for chemotherapy-related nausea and vomiting, and dronabinol separately for appetite loss associated with HIV/AIDS. It has also approved one plant-derived CBD drug, but only for two rare seizure disorders. None of the FDA’s cannabis-related approvals cover pain, sleep or anxiety. The agency has also said it has seen only limited safety data on CBD, and that the data it has seen point to real risks — including liver injury and drug interactions — that should be discussed with a healthcare provider before use, in a market full of unapproved products making unproven claims.
That regulatory gap is exactly why non-cannabis options with a longer evidence trail are worth knowing before any product-specific claim gets evaluated. If you arrived here after reading about a specific CBD product’s billing terms and refund process, this is the decision that logically comes first: what you’re actually trying to treat, and what’s been shown to help it, before any purchase enters the picture.
Your next step
From here there are three reasonable paths, and all three are legitimate: get a professional assessment to match your specific diagnosis to an evidence-graded option, try one of the approaches above on your own using the worksheet to track it, or decide you don’t have enough information yet and hold off on any purchase. There’s no wrong answer among the three — only the one that fits what you’re actually dealing with.